

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2010

AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas VasANJI Road,
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 31.03.2010 (Unaudited)	Quarter ended 31.03.2009 (Unaudited)	Year ended 31.12.2009 (Audited)
1 (a) Net Sales	2,514	2,289	9,744
(b) Other Operating Income	169	226	781
Total	2,683	2,515	10,525
2 Expenditure			
(a) Increase/Decrease in stock in trade and work in progress	10	(141)	(623)
(b) Consumption of raw materials	837	947	3,525
(c) Purchase of traded goods	414	304	1,918
(d) Employee cost	376	326	1,440
(e) Depreciation	43	42	173
(f) Other expenditure	513	463	2,006
(g) Total	2,193	1,941	8,439
3 Profit from operations before other income and interest(1-2)	490	574	2,086

Particulars	Quarter ended 31.03.2010 (Unaudited)	Quarter ended 31.03.2009 (Unaudited)	Year ended 31.12.2009 (Audited)
4 Other Income	57	94	330
5 Profit before Interest(3+4)	547	668	2,416
6 Interest	-	-	1
7 Profit before tax(5-6)	547	668	2,415
8 Tax Expenses	186	263	841
9 Net Profit for the period(7-8)	361	405	1,574
10 Paid-up equity share capital (Face Value of Rs. 10 per Share)	230	230	230
11 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year			8,916
12 Earnings Per Share (EPS) (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year	15.70	17.61	68.35
13 Public Shareholding			
- Number of Shares	9,121,035	9,120,955	9,120,955
- Percentage of Shareholding	39.60	39.60	39.60
14 Promoters and Promoter group shareholding			
a) Pledged/Encumbered			

Particulars	Quarter ended 31.03.2010 (Unaudited)	Quarter ended 31.03.2009 (Unaudited)	Year ended 31.12.2009 (Audited)
- Number of Shares	-	2,365,920	2,365,920
- Percentage of shares(as a % of shareholding of promoter and promoter group)	-	17.01%	17.01%
- Percentage of shares(as a % of total share capital of the company)	-	10.27%	10.27%
b) Non-Encumbered			
- Number of Shares	13,909,587	11,543,747	11,543,747
- Percentage of shares(as a % of total shareholding of promoter and promoter group)	100.00%	82.99%	82.99%
- Percentage of shares(as a % of total share capital of the company)	60.40%	50.13%	50.13%

Notes:

- The above Results were approved by the Board of Directors of the Company at its Meeting held on April 27, 2010.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended March 31, 2010.
- Hoechst GmbH a promoter and the Company's holding company, has acquired, on March 30, 2010, 2,366,380 Equity Shares held by four companies in the Promoter Group by way of inter se transfer amongst promoters. As a result of the acquisition, Hoechst GmbH and its holding company, Sanofi-Aventis SA, France now hold 13,909,587 Shares constituting 60.40% of the paid-up share capital of the Company. Dr Vijay Mallya, who will continue as Chairman of the Company, has informed the Company that he will no longer be a Promoter or part of the Promoter Group of the Company.

- The Board of Directors had, at its Meeting held on February 24, 2010, recommended a Final dividend of Rs.16.50 per Equity share of Rs. 10 for the year ended December 31, 2009. The said dividend, if declared at the Annual General Meeting to be held on April 27, 2010, will be paid on or after April 28, 2010.
- The break up of Net Sales is as follows:

Rs Million

	Quarter ended March 31, 2010	Quarter ended March 31, 2009	Growth %
Domestic Sales-Others	1,972	1,621	21.7%
Domestic Sales-Rabipur	-	92	-100.0%
Export Sales	542	576	-5.9%
Total Sales	2,514	2,289	9.8%

Excluding the impact of discontinuation of Rabipur distribution, comparable sales growth for the quarter ended March 31, 2010 is 14.4%.

- Throughout 2010, the Company will incur planned expenditure in two critical projects-slanted to be growth drivers :
 - a) "Prayas"- a project to deliver high quality low cost healthcare to the rural population ; and
 - b) Entering the Over The Counter (OTC) market.
 These initiatives are expected to deliver long term prospects for the Company.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- Information on investor complaints is furnished below:

Pending as on January 1, 2010	Received during the quarter	Disposed of during the quarter	Pending as on March 31, 2010
Nil	13	13	Nil

- The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED

DR. SHAILESH AYYANGAR
MANAGING DIRECTOR